Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03978520
Recruitment Status : Recruiting
First Posted : June 7, 2019
Last Update Posted : February 12, 2021
Sponsor:
Information provided by (Responsible Party):
AbbVie

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 17, 2021
Estimated Study Completion Date : July 2, 2022